Skin reactions to the new biologic anticancer drugs

Current Opinion in Supportive and Palliative Care

Volumn 3, Issue 4, 2009, Pages 294-299

  Myskowski, Patricia L ^a   Halpern, Allan C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Skin toxicity; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR;

ARTICLE; DRUG ERUPTION; HUMAN; NEOPLASM;

ANTINEOPLASTIC AGENTS; BIOLOGICAL FACTORS; DRUG ERUPTIONS; HUMANS; NEOPLASMS;

EID: 74549145537     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328332d397     Document Type: Article

References (39)

1. Capdevila J, Elez E, Macarulla T, et al. Antiepidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 2009; 35:354-363.
2. Fakih M. The role of targeted therapy in the treatment of advanced colorectal cancer. Curr Treat Options Oncol 2008; 9 (4-6):357-374; Epub 2009 Feb 24.
3. Bastien L, Culine S, Paule B, et al. Targeted therapies in metastatic renal cancer in 2009. BJU Int 2009; 103:1334-1342; Epub 2009 Mar 11.
4. Zahorowska B, Crowe PJ, Yang JL. Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol 2009; 135:1137-1148.
5. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in nonsmallcell lung cancer management. Clin Lung Cancer 2009; 10:28-35.
6. Myskowski PL, Halpern AC. Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. Curr Allergy Asthma Rep 2008; 8:63-68.
7. Robert C, Soria J-C, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet 2005; 6:491-500.
8. Fraunfelder FW, Solomon J, DrukerBJ, et al. Ocular side effects associated with imatinib mesylate (Gleevac). J Ocul Pharmacol Ther 2003; 19: 371-375.
9. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to ST1571 (Gleevac). Cancer 2002; 95:881-887.
10. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006; 5:228-231.
11. Snyder D. New approved dasatinib regimen available for clinical use. Expert Rev Anticancer Ther 2009; 9:285-292.
12. Khoury HJ, Guilhot F, Hughes TP, et al. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer 2009; 115:1381-1394.
13. Sun A, Akin RS, Cobos E, Smith J. Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. J Drugs Dermatol 2009; 8:395-398.
14. Argyriou AA, Kalofanos HP. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med 2009; 15:183-191.
15. Laux I, Jain A, Singh S, Agus DB. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006; 94:85-92.
16. Lacouture ME, Laabs SM, Koehler M, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2009; 114:485-493.
17. Gridelli C, Maione P, Amoroso D, et al. Clinical significance and treatment of skin rash from erlotinib in nonsmall cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Oncol Hematol 2008; 66:155-162.
18. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4:107-119.
19. Burtness B, Anadkat M, Basti S, et al. NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009; 7 (Suppl 1):S5-S23. It is the most comprehensive overview on treatment of these increasingly common and important cutaneous toxicities.
20. Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007; 357:514-515.
21. Tejwani A, Wu S, Xia J, et al. Increased risk of high-grade skin toxicity with EGFR inhibitors plus radiotherapy. Cancer 2009; 115:1286-1299.
22. Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19:142-149.
23. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-1664.
24. Segaret S, Van Cutsem E. Clinical management of EGFR1 dermatologic toxicities: the European perspective. Oncology (Williston Park) 2007; 21 (11 Suppl 5):22-26.
25. Lacouture ME, Cotliar J, Mitchell EP. Clinical management ofEGFR1 toxicities: US perspective. Oncology (Williston Park) 2007; 21 (11 Suppl 5):17-21.
26. Yamazaki N, Muro K. Clinical management of EGFR1 dermatologic toxicities: the Japanese perspective. Oncology (Williston Park) 2007; 21 (11 Suppl 5): 27-28.
27. Melosky B, Burkes R, Rayson D, Alcindor T, et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009; 16:16-26.
28. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25:5390-5396.
29. Scope A, Lieb JA, Dusza SW, et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption. J Am Acad Dermatol 2009; 61:614-620.
30. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113:847-853.
31. Lacouture ME, Mitchell EP, Shearer H, et al. Impact of preemptive skin toxicity (ST) treatment (tx) on panitumumab (pmab)-related skin toxicities and quality of life (QOL) in patients (pts) with metastatic colorectal cancer (mCRC): Results from STEPP [abstract]. ASCO Gastrointestinal Cancers Symposium 2009; 291.
32. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009; 43:490-501. Good, current review of bevacizumumab reactions.
33. Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care 2009; 3:170-179.
34. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158:592-596.
35. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination antivascular endothelial growth factor therapy. Clin Cancer Res 2009; 15:1411-1416.
36. Suwattee P, Chow S, Berg BC, Warshaw EM. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol 2008; 144:123-125.
37. Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and nonrenal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009; 7:11-19.
38. Lacouture ME, Wu S, Robert C, Atkins MB, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13:1001-1011; Epub 2008 Sep 8. Update on management of skin reactions of these multikinase inhibitors.
39. Anderson R, Jatoi A, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009; 14:291-302.